# GLP-1 Kidney Disease Research: What 4 Major Trials Found **By TelosRX Editorial Team** · 2026-08-20 **GLP-1 kidney disease research has shifted how clinicians think about semaglutide — it's no longer just a weight-loss drug. At [TelosRX](https://telosrx.com), we track the evidence so you can have better conversations with your provider.** If you've heard about GLP-1 medications for weight management, here's something you may not know: four major clinical trials now show these drugs may protect kidney function in people with chronic kidney disease (CKD). The most significant — the FLOW trial — was the first trial ever designed specifically to answer that question. This article walks through what each study actually found, what the numbers mean, and what limits the evidence. No outcome guarantees. Just the data. ## Why GLP-1 Agonists Might Protect the Kidneys GLP-1 receptors exist throughout the body — not just in the gut and brain. They're found in kidney tissue too. When activated, they may reduce inflammation, lower intraglomerular pressure (the filtration pressure inside kidney structures called glomeruli), and decrease albuminuria, which is protein leakage in urine that signals kidney stress. Proposed mechanisms include: - **Blood pressure reduction** — a primary driver of CKD progression - **Lower oxidative stress and inflammation** in renal tissue - **Improved glycemic control**, which limits sugar-related kidney damage over time - **Weight loss**, which reduces the metabolic load on kidney filtration These are mechanistic hypotheses supported by preclinical and observational research. Clinical trials are what test them in real patients at scale. Here's what four major trials found. ## The FLOW Trial: First Dedicated Kidney Outcomes Study The FLOW trial (Evaluate Renal Function with Semaglutide Once Weekly) was the landmark study here. It enrolled 3,533 adults with type 2 diabetes and CKD across 28 countries and randomly assigned them to weekly semaglutide 1.0 mg or placebo — on top of standard kidney-protective care. **Primary endpoint:** Composite of kidney failure, sustained ≥50% decline in eGFR (estimated glomerular filtration rate), or death from renal or cardiovascular causes. Result: Semaglutide reduced this composite endpoint by **24%** versus placebo. That's a statistically significant and clinically meaningful finding for a population that has historically had few slowing-the-clock options. Additional FLOW results worth noting: - Annual eGFR decline slowed by 1.16 mL/min/1.73m² in the semaglutide group - Urinary albumin-to-creatinine ratio (UACR) dropped by 38% — a key marker of glomerular stress - Benefits were consistent across all CKD severity levels studied - Kidney protection was observed regardless of whether patients were also on SGLT-2 inhibitors FLOW Trial Measure Semaglutide Group Placebo Group Effect Composite kidney endpoint (kidney failure / eGFR ≥50% decline / renal or CV death) Lower incidence Higher incidence 24% relative risk reduction Annual eGFR decline Slower Faster –1.16 mL/min/1.73m²/year UACR reduction 38% lower Minimal change Significant reduction in albuminuria Cardiovascular outcomes Reduced Higher Consistent benefit observed Source: [FLOW Trial, Kidney and Survival Outcomes by CKD Severity (PubMed, 2025)](https://pubmed.ncbi.nlm.nih.gov/41706532/) ## The SELECT Trial: Kidney Protection Without Diabetes The SELECT trial enrolled 17,604 adults — none with diabetes — who had obesity and established cardiovascular disease. Its primary purpose was cardiovascular outcomes. But a prespecified kidney analysis found something notable. Participants taking semaglutide 2.4 mg weekly had a **22% lower risk of composite kidney outcomes** compared to placebo. This included sustained decline in eGFR and kidney-related death. Why does this matter? The SELECT population wasn't selected for CKD. They weren't chosen because their kidneys were already struggling. The kidney benefit appeared in a broad obesity population — suggesting the mechanism may extend beyond glucose control and into weight reduction and inflammation alone. Source: [SELECT Trial Kidney Analysis, NCT (PMC, 2025)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12277595/) ## LEADER and SUSTAIN-6: Early Signals Before FLOW, kidney effects were secondary findings in cardiovascular outcomes trials. **LEADER (liraglutide):** In 9,340 adults with type 2 diabetes and high cardiovascular risk, liraglutide reduced new or worsening nephropathy by 22% versus placebo. This was among the first credible signals that GLP-1 agonists might have direct renal effects beyond glycemic control. **SUSTAIN-6 (semaglutide injectable):** This smaller trial (3,297 participants) found nephropathy occurred in 3.8% of the semaglutide group vs. 6.1% of the placebo group. Directionally consistent — but the trial was powered for cardiovascular endpoints, so the kidney finding was exploratory. These trials created the scientific hypothesis FLOW was designed to confirm. ## What the Research Doesn't Show (Limitations) Being clear about what the evidence does and doesn't prove matters here: - **FLOW enrolled people with type 2 diabetes and CKD.** Evidence is strongest for that specific population. SELECT suggests broader applicability, but that population had different baseline characteristics. - **These are not cure or treatment findings** for kidney disease. GLP-1 medications used through compounding are not FDA-approved to treat, cure, or prevent CKD. They're prescribed for weight management under clinical oversight. - **GI side effects require monitoring.** Nausea, vomiting, and dehydration — common early side effects — can stress kidneys with limited reserve. Provider monitoring is essential in people with CKD. - **Individual results vary.** A 24% relative risk reduction in a trial population is an average across thousands of people. Your individual response depends on your specific health profile. If you're curious whether a GLP-1 evaluation makes sense for your situation, [TelosRX's](https://telosrx.com) asynchronous intake process allows a licensed provider to review your health history before any prescribing decision is made — subject to medical approval by a licensed provider. ## GLP-1 Kidney Research: The Bigger Picture Something has shifted in how researchers categorize GLP-1 medications. Semaglutide was initially approved for glycemic control in type 2 diabetes. Then for weight management. Now the FLOW trial's results have led researchers to call for reconceptualizing GLP-1 agonists as "cardio-renal-metabolic" agents — drugs with meaningful effects across multiple organ systems, not just body weight. That framing has real implications. If GLP-1 medications are disease-modifying agents for metabolic syndrome, the case for early access becomes stronger — not to prevent kidney disease (no approved claim) but as part of broader metabolic care where kidneys happen to benefit. For context on how these medications work mechanically, see our overview of [how GLP-1 receptor agonists work](https://www.telosrx.com/blogs/glp1/how-does-glp1-work-mechanism-weight-loss) and our breakdown of [semaglutide benefits beyond weight loss](https://www.telosrx.com/blogs/glp1/semaglutide-benefits-beyond-weight-loss). ## Frequently Asked Questions ### Does semaglutide damage the kidneys? The major clinical trials — FLOW, SELECT, LEADER, SUSTAIN-6 — do not show kidney damage from semaglutide. In fact, they show the opposite: lower rates of kidney function decline compared to placebo. That said, GI side effects like nausea and dehydration require monitoring in people with existing CKD, since these can strain kidney reserve. This is a conversation for your provider, not a blanket contraindication. ### Can GLP-1 medications help slow kidney disease progression? The FLOW trial found semaglutide reduced major kidney outcomes by 24% in people with type 2 diabetes and CKD. Compounded GLP-1 medications are not FDA-approved to treat, cure, or prevent kidney disease. Prescription is subject to medical approval by a licensed provider based on individual health evaluation. ### What is the FLOW trial, and why does it matter? FLOW (Evaluate Renal Function with Semaglutide Once Weekly) was the first randomized clinical trial designed specifically to study GLP-1 effects on kidney outcomes. Its 3,533 participants had type 2 diabetes and CKD. Semaglutide reduced the composite kidney endpoint by 24% — the largest kidney-protective signal from a GLP-1 trial at the time of publication. ### Is compounded semaglutide FDA-approved for kidney disease? No. Compounded semaglutide is not FDA-approved for the treatment or prevention of kidney disease. It is prepared under federal compounding regulations and prescribed for weight management purposes under clinical oversight. Research showing kidney-protective effects in clinical trials does not create an FDA-approved indication for CKD. ### Can I take semaglutide if I already have chronic kidney disease? That depends on your specific kidney function, current medications, and overall clinical picture. TelosRX's asynchronous provider review evaluates your health history before any prescription is issued. Approval is not guaranteed. People with moderate to severe CKD require careful monitoring due to dehydration risk from GI side effects. ### What does eGFR decline mean, and why does it matter? eGFR (estimated glomerular filtration rate) measures how effectively your kidneys filter waste from blood. A declining eGFR indicates kidney disease progression. The FLOW trial found semaglutide slowed annual eGFR decline by 1.16 mL/min/1.73m² — which sounds small but compounds meaningfully over years in a population already losing function. ### Do other GLP-1 agonists protect the kidneys too? The strongest evidence is for semaglutide (FLOW trial). Liraglutide (LEADER trial) showed earlier signals of kidney benefit. Dulaglutide has shown UACR reduction in some studies. Tirzepatide (a GLP-1/GIP dual agonist) has cardiovascular outcomes data but no equivalent dedicated kidney outcomes trial as of mid-2026. Research is ongoing. _TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service._ Start your private evaluation at [TelosRX](https://telosrx.com). **Tags:** FLOW trial, GLP-1 kidney disease, kidney outcomes, research-evidence, semaglutide CKD, semaglutide research --- > Source: [Telos RX](https://www.telosrx.com/blogs/glp1/glp1-kidney-disease-research-what-trials-show)